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Abstract: Intolerance to carbohydrates is relatively common in childhood, but still poorly recognized
and managed. Over recent years it has come to the forefront because of progresses in our knowledge
on the mechanisms and treatment of these conditions. Children with intolerance to carbohydrates
often present with unexplained signs and symptoms. Here, we examine the most up-to-date research
on these intolerances, discuss controversies relating to the diagnostic approach, including the role
of molecular analysis, and provide new insights into modern management in the pediatric age,
including the most recent evidence for correct dietary treatment.
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1. Introduction
Adverse food reactions (AFR) represent a relevant problem in daily clinical practice, but are poorly
recognized and managed. They are common in industrialized countries, where, depending on data
collection methods and definitions, they affect up to 20% of the general population [1]. The prevalence
increases significantly in patients with irritable bowel syndrome (IBS). It has been described that up to
80% of IBS patients believe that their symptoms are diet-related, of which three quarters are possibly
related to intolerance to carbohydrates [2,3].
According to the main pathophysiologic mechanism, AFRs are commonly classified into different
groups (Figure 1) [4–8].
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2).  The  prevalence  of  this  condition  has  seemed  to  increase  during  the  last  few  decades  as  a 
consequence of the growing rate of carbohydrate consumption in the diet. National survey data in 
the  United  States  have  indicated  that,  over  the  past  few  decades,  consumption  of  selected 
carbohydrates, largely in the form of added sugars, has increased by up to 900% [9]. 
 
Figure  2.  Classification  of  carbohydrate  intolerances.  CSID:  Congenital  Sucrase‐Isomaltase 
Deficiency; GGM: Glucose‐Galactose Malabsorption; CLD: Congenital Lactase Deficiency. 
Symptoms  of  intolerance  to  carbohydrates  are  primarily  due  to  deficiency  of  enzymes  or 
transporters or overloading of  a  transport  system  located on  the brush border of  the  epithelium 
lining the small intestine (Figure 3). Non‐absorbed carbohydrates in the intestinal tract drive fluids 
into  the  lumen  through  an  osmotic  force,  causing  osmotic  diarrhea.  Moreover,  non‐absorbed 
carbohydrates are fermented by gut microbiota to gas. 
Figure 1. Classification of adverse food reactions ( FR).
Intolerance to carbohydrates is the most common type of non-immune-mediated AFR (Figure 2).
The prevalence of this condition has seemed to increase during the last few decades as a consequence
of the growing rate of carbohydrate consumption in the diet. National survey data in the United States
have indicated that, over the past few decades, consumption of selected carbohydrates, largely in the
form of added sugars, has increased by up to 900% [9].
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Figure 2. Classification of carbohydrate intolerances. CSID: Congenital Sucrase-Isomaltase Deficiency;
GGM: Glucose-Galactose Malabsorption; CLD: Congenital Lactase Deficiency.
Symptoms of intolerance to carbohydrates are primarily due to deficiency of enzymes or
transporters or overloading of a transport system located on the brush border of the epithelium
lining the small intestine (Figure 3). Non-absorbed carbohydrates in the intestinal tract drive fluids into
the lumen through an osmotic force, causing osmotic diarrhea. Moreover, non-absorbed carbohydrates
are fermented by gut microbiota to gas.








All  these  events  are  responsible  for  the  clinical  symptoms,  such  as  distension  of  the  small 
bowel,  non‐focal  abdominal  pain  associated with  bloating  and  flatulence,  nausea,  increased  gut 
motility,  and  diarrhea  [2,10–14].  Extraintestinal  symptoms,  such  as  headache,  vertigo,  memory 
impairment,  and  lethargy  have  been  described  in  less  than  20%  of  subjects  with  carbohydrate 
intolerance [15,16]. These systemic symptoms could be the result of toxic metabolites, produced by 
sugar fermentation of colonic bacteria, that can alter cell signalling mechanisms (Figure 4).  
Figure 3. Mechanisms involved in main carbohydrate intolerances. (A) Lactose intolerance due to
deficiency of lactase enzyme; (B) glucose-galactose malabsorption due to a genetic defect in SGLT1
expression; (C) fructose malabsorption due to dose-dependent transporters overloading; (D) sucrase
malabsorption due to a genetic defect in sucrase-isomaltase activity.
All these events are responsible for the clinical symptoms, such as distension of the small bowel,
non-focal abdominal p in associated with bloating and flatulence, nause , increased gut tility,
and di rh a [2,10–14]. Extraint stinal symptoms, such as headache, vertigo, memory impairm nt,
and lethargy have been d scrib d in less han 20% of subj cts with carbohydrate intolerance [15,16].
These syste ic symptoms could be the result of toxic metabolites, produced by su a fermentation of
colonic bacteria, that can alter cell signalling mechanisms (Figure 4).
These manifestations frequently lead to investigations to rule out other organic disorders at
intestinal and extra-intestinal levels, including invasive procedures. Thus, there is a large unmet
need for a clear diagnosis as well as consistent and effective advice on dietary treatments for these
conditions. There have been significant advances in understanding the scientific basis of carbohydrate
intolerances, and new forms (e.g., Fermentable Oligosaccharides, Disaccharides, Monosaccharides,
and Polyols intolerance, and non-celiac gluten sensitivity) have been identified [1,14]. Intolerance to
carbohydrates often begins in childhood. Here, we examine the most up-to-date research on childhood
intolerance to carbohydrates, discuss controversies relating to the diagnostic approach, including the
role of molecular analysis, and provide new insights into the modern management of these conditions.
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inherited disease of  the small  intestine resulting  from genetic mutations  in sucrase‐isomaltase, an 
enzyme  complex  responsible  for  catalyzing  the  hydrolysis  of  dietary  sucrose  and  starch  [17]. 
Decreased or absent sucrase and/or isomaltase enzymatic activity has been found  in patients with 
CSID, and investigations at the subcellular and molecular levels in intestinal biopsy specimens have 
led  to  the  description  of  several  phenotypes,  differing  in  transport  efficiency,  processing,  and 
sorting of  the protein, which  result  in  impaired physiologic  functions  [17–20].  In addition  to  the 
degree of  enzyme deficiency,  the appearance of overt  clinical manifestations of CSID  is partially 
determined  by  the  amount  of  sugar  and  starch  consumed  [21]. The prevalence  in  the European 
population has been estimated at 1  in 5000, but  it  is higher among  the  indigenous populations of 
Alaska, Greenland,  and Canada  [22]. Gastrointestinal  symptoms  usually  begin  after  an  infant  is 
weaned off breast milk and  is  first  exposed  to  sucrose  and  starch  [23]. Failure  to  absorb dietary 
disaccharides and starch has  implications  for  the absorption of other nutrients and  the hormonal 
regulation of gastrointestinal function. For these reasons, patients with CSID are at risk for chronic 
malnutrition and failure to thrive. In many cases, the symptoms of CSID are more severe in infants 
than  in  adults.  It  has  been  suggested  that  an  increased  susceptibility  to  symptoms  in  infants  is 
related to a shorter length of the small intestine. Although intestinal biopsy is still adopted in many 
Figure 4. Pathogenesis of gut and brain symptoms in patients with intolerance to carbohydrates.
2. Genetic Etiology with Early Onset Carbohydrate Intolerances
2.1. Congenital Sucrase-I om ltase Deficiency (CSID)
Congenital sucrose-isomaltase deficiency (CSID, OMIM #222900) is a rare autosomal recessive
inherited disease of the small intestine resulting from genetic mutations in sucrase-isomaltase, an
enzyme complex responsible for catalyzing the hydrolysis of dietary sucrose and starch [17]. Decreased
or absent sucrase and/or isomaltase enzymatic activity has been found in patients with CSID, and
investigations at the subcellular and molecular levels in intestinal biopsy specimens have led to the
description of several phenotypes, differing in transport efficiency, processing, and sorting of the
protein, which result in impaired physiologic functions [17–20]. In addition to the degree of enzyme
deficiency, the appearance of overt clinical manifestations of CSID is partially determined by the
amount of sugar and starch consumed [21]. The prevalence in the European population has been
estimated at 1 in 5000, but it is higher among the indigenous populations of Alaska, Greenland, and
Canada [22]. Gastrointestinal symptoms usually begin after an infant is weaned off breast milk and
is first exposed to sucrose and starch [23]. Failure to absorb dietary disaccharides and starch has
implications for the absorption of other nutrients and the hormonal regulation of gastrointestinal
function. For these reasons, patients with CSID are at risk for chronic malnutrition and failure to thrive.
In many cases, the symptoms of CSID are more severe in infants than in adults. It has been suggested
that an increased susceptibility to symptoms in infants is related to a shorter length of the small intestine.
Although intestinal biopsy is still adopted in many tertiary centers for CSID diagnosis, genetic testing
is now widely available. Molecular genetics has become helpful for obtaining an early and unequivocal
diagnosis in infants with chronic diarrhea due to any of a variety of different disorders, thus permitting
rapid and targeted therapeutic strategies and reducing repetitive, invasive, and expensive procedures.
At least 80% of CSID patients have one of four common mutations [22,24]. Three of these four
mutations (p.Val577Gly, p.Gly1073Asp, and p.Phe1745Cys) are in the sucrase domain and have been
identified previously for their role in cellular trafficking. They have been confirmed to abolish sucrase
and isomaltase activity. The fourth mutation, p.Arg1124X, in the isomaltase domain, introduces
a chain termination codon and interrupts the amino acid coding sequence [24]. Other diagnostics
are also available, but less used in clinical practice, such as sucrose breath hydrogen tests [25] and
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intestinal disaccharidases activity measurement on biopsy specimens [20]. In the treatment of CSID,
the administration of an oral solution containing sacrosidase (Sucraid) as enzyme replacement therapy
could be helpful, along with dietary restriction (Table 1). This enzyme, derived from the Saccharomyces
cerevisiae, is generally well tolerated in patients with CSID and induces a reduction of symptoms by
helping sucrose digestion [21,26].
Table 1. Low sucrose diet.
Foods to avoid
Cereals with added sugars
Apple, apricot, banana, cantaloupe, grapefruit, melon, mango, orange, peach, pineapple, tangerine
Carrot, potato
Beans, chickpeas, green peas, lentils, peas, soy
Yogurt sweetened with sucrose, sweetened condensed milk, sweetened cream
Sugar (sucrose), ice cream, all desserts made with sugar, marmalade, candies, jellies, chocolate, licorice,
commercial cookies and cakes with added sugar, sweetened drinks
Foods allowed
Wheat, rice, corn, einkorn, oats, kamut, spelt, rye, bread, pasta, flour, cereals with no added sugar *
Avocado, berries, cherries, fig, grapes, kiwi, lemon, lime, olives, papaya, pear, pomegranate, prune,
strawberries
All vegetables
Milk, dairy product, butter, cream, cheeses, yogurt sweetened with dextrose or fructose
All meat, fish, and eggs
All fats
Fructose, honey, cocoa, unsweetened juice, homemade low-sucrose cookies and cakes
* In patients who can ingest starch at 40–50 grams per serving two to three times per day.
2.2. Glucose-Galactose Malabsorption
Glucose-galactose malabsorption (GGM, OMIM 606824) is a rare autosomal recessive disorder
caused by a defect in the solute carrier family 5 member 1 gene SLC5A1, which codes for a Na+/glucose
co-transporter [27]. This transporter is responsible for the tight coupling of two Na+ ions and one
glucose or galactose molecule across the membrane of the epithelial cells lining the small intestine
and renal proximal tubule [28]. The prevalence of this condition is still unknown, because only a few
hundred cases have been described. Patients with congenital GGM present with severe, life-threatening
chronic diarrhea. The malabsorbed glucose and galactose, and derived short chain fatty acids (SCFAs),
reaching the colon determine osmotic diarrhea. Many patients present an improvement of symptoms
in adulthood, because of a better absorption of sugars, but the underlying mechanism is unclear.
A tentative diagnosis of GGM is based on the following criteria: (1) onset of diarrhea soon after birth;
(2) evidence of carbohydrate malabsorption with positive reducing substance in the stool; (3) failure
to improve with lactose free and amino acid based formula; (4) strong improvement of diarrhea only
with elimination of glucose and galactose; (5) exclusion of infections. The diagnosis can be confirmed
by molecular analysis of the SLC5A1 gene [29–32]. More than 40 mutations of SLC5A1 responsible for
GGM have been described, but a real genotype/phenotype correlation is still lacking. This modern
approach has replaced other diagnostic tests such as hydrogen breath test with glucose or galactose [33],
or the oral glucose/galactose tolerance test [34]. Patients with GGM improve their symptoms with a
specific low concentration of glucose-galactose in the diet and using a fructose formula in early life
(Table 2).
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Table 2. Low glucose and galactose diet.
Foods to avoid
All kinds of milk, butter, yogurt, cheeses and other dairy products
Sugar (sucrose), ice cream, all desserts made with sugar, candies, gelatin desserts, chocolate, licorice,
commercial cookies and cakes with added sugar, sweetened drinks
Glucose, dextrose, dextrin, maltose, maltodextrin, corn syrup, glucose polymers, lactose, stevia
Foods allowed
Special formula without galactose and glucose
Small amounts of: pasta, rice, potatoes, bread, unsweetened cereal, puffed wheat, puffed rice, oat, wholegrain
cereals without a sugary coating, quinoa
All legumes (beans, chickpeas, peas, lentils, soy)
All vegetables
All fruits
All meat, fish, and eggs
All vegetable fats
Fructose, honey, cocoa, sugar-free marmalade, unsweetened juice, all fructose-sweetened desserts and snacks
3. Genetic Etiology with Late-Onset Carbohydrate Intolerances
Lactose Intolerance
According to the origin, lactose intolerance can be classified into three main forms:
1. Congenital lactase deficiency: a rare autosomal recessive disease where enzymatic activity is
absent or reduced from birth;
2. Secondary lactase deficiency: a transient condition deriving from intestinal damage secondary to
small bowel bacterial overgrowth, infections, celiac disease, Crohn’s disease, or radiation enteritis;
3. Adult type lactase deficiency: an autosomal recessive condition resulting from a developmentally
regulated change of the lactase gene product, responsible for reduced synthesis of the
precursor protein.
Congenital lactase deficiency (CLD, MIM 223000) is a very rare (only a few cases have been
described) and severe form of lactase deficiency in which this enzymatic activity is very low or absent
from birth [35]. The main symptoms are watery diarrhea, meteorism, and malnutrition, beginning on
the first days after birth with the onset of lactation. Symptoms disappear when patients change to a
lactose-free diet. The typical feature of CLD is very low levels of lactase-phlorizin hydrolase (LPH),
the enzyme responsible for the digestion of lactose. The activities of other disaccharidases and the
histological structure of the epithelium of the small intestine are normal [36]. Most CLD cases have
been described in Finland, where the disorder is enriched due to a founder effect and genetic drift [36].
This is in contrast to adult-type hypolactasia (where lactase activity declines after weaning), which is
common all over the world [36]. Premature stop codons and a truncated protein as a result of frame
shifts, missense mutations in the coding region of LPH, or exon duplication are the most common
genotypes identified in CLD patients [35–38]. Some other cases include mutations leading to single
amino acid substitutions that can interfere with the proper maturation and function of LPH [36,39].
Recently, severe forms of CLD elicited by mutations in the LPH gene that occur in either a compound
heterozygous or homozygous pattern of inheritance have been described [40].
In about 70% of the worldwide general population, LPH activity decreases below a critical
threshold between the ages of two and five years; this is the most frequent cause of enzyme
deficiency [12,41,42]. The rate of adult type lactase deficiency varies among ethnic groups (e.g., Asia
80% to 100%, Africa 70% to 95%, USA 15% to 80%, Europe as a whole 15% to 70%) and is based on the
non-persistence of LPH after childhood [42]. The persistence or non-persistence (hypolactasia) of the
expression of LPH is associated with the point polymorphism C/T 13910. This consists of a substitution
in a sequence of DNA that regulates the LPH gene: genotype CC correlate with hypolactasia, while
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TT genotype with lactase persistence [43]. Several individual factors influence the development of
symptoms in non-persistence lactase subjects: dose of lactose in diet, oro-cecal transit time, lactase
expression, distribution and fermentation capacity of gut flora [44], sensitivity towards chemical
and mechanical stimulation of the gut, and psychological factors [45,46]. Adaptation of intestinal
microbiota, assuming a growing dose of lactose, with increase of bacterial b-galactosidase activity is
recognized as a cause of reduction of the symptoms of lactose intolerance [47,48]. Anamnesis and
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Figure 5. Breath test procedures in children with suspected carbohydrate intolerances.
Another available diagnostic test is the lactose tolerance test (LTT), in which a patient suspected
of lactose intolerance assumes 50 g of lactose dissolved in water. Samples of capillary blood are taken
to test the plasma glucose concentration at ´5, 0, 15, 30, 45, and 60 min. A maximal plasma-glucose
increase of 1.4 mmol/L or higher indicates lactose tolerance [49]. A meta-analysis comparing the
diagnostic accuracy of lactose breath hydrogen or lactose tolerance tests found that the overall
sensitivity was 0.88 (confidence interval [CI], 0.85–0.90) and the specificity was 0.85 (CI, 0.82–0.87) for
the breath test. The lactose tolerance test showed a sensitivity of 0.94 (CI, 0.9–0.97) and a specificity of
0.90 (CI, 0.84–0.95) [50]. The genetic test, identifying single nucleotide polymorphism associated with
lactase persistence/non-persistence, is also available. It should be noted that the presence of the lactase
non-persistent gene does not imply the simultaneous presence of lactose intolerance that may appear
later in the life. More recently, a test based on the measurement of D-xylose after lactase cleavage
of orally administered 4-galactosylxylose (Gaxilose) has been investigated in a large multicenter
study in adults, with good sensitivity and specificity for lactase deficiency as determined in biopsy
specimens [51].
Management of lactose intolerance consists in the avoidance of all lactose-containing foods
(Tables 3 and 4) [52]. In adult-type hypolactasia, dairy products are generally avoided for 2–4 weeks,
the time required for remission of symptoms. Then, a gradual reintroduction of dairy products low
in lactose up to a threshold dose of individual tolerance should be recommended. In secondary
hypolactasia, a restricted diet is necessary only for a limited time period. [53]. Available data suggest
that adults and adolescents with a diagnosis of lactose intolerance could ingest up to 12 g of lactose
in a single dose (equivalent to the lactose content in 1 cup of milk) without any symptoms or with
only minor symptoms [53]. Products containing lactic acid, lactalbumin, lactate, and casein do not
contain lactose, so they can be consumed [53]. The oral administration of Beta-Galactosidase represents
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another possible therapeutic approach for the treatment of primary lactase deficiency. The data
showed an improvement of gastrointestinal symptoms and a decrease of H2 levels at breath test with
the administration of 1500 U/day of Beta-Galactosidase. However, data regarding the efficacy of this
microbial exogenous enzyme are still needed [54] Yogurt with live cultures is generally well tolerated
by individuals with lactose intolerance.
Table 3. Lactose content in common dairy foods.
Food Lactose (g/100 g of Food)
Skimmed cow’s milk 4.7
Low-fat cow’s milk 4.6
Whole cow’s milk 4.5
Buttermilk 4.1
Free lactose milk 0.5
Whole powdered milk 35.1















Table 4. Low lactose diet.
Foods to limit
All kinds of milk: whole, low fat, nonfat, cream, powdered, condensed, evaporated, goat, acidophilus,
and chocolate
Butter, cottage cheese, ice cream, creamy/cheesy sauces, cream cheeses, soft cheeses (brie, ricotta), mozzarella,
whipped cream, yogurt
Fish and meat (breaded or creamed)
Milk bread, crackers, creamed, scalloped, or au gratin potatoes
Muffin, biscuit, waffle, pancake, and cake mixes; milk chocolate; bakery products and desserts that contain the
ingredients listed above
Foods allowed
Lactose-free milk, soy milk






All meat, fish, and eggs
All vegetable fats
Subjects with lactose intolerance could be at risk of lower calcium intake, so calcium
supplementation is required and the recommendation of calcium fortified foods should be considered.
The current recommendations for calcium intake are 700 mg/day for children aged 4 to 9 years, and
1300 mg/day over 10 years, according to EFSA guidelines [55].
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4. Non-Genetic Etiology Carbohydrate Intolerances
4.1. Fructose Malabsorption
Fructose is a six–carbon monosaccharide molecule naturally present in a great variety of daily
foods, such as fruits, vegetables, and honey [56]. It is also produced through enzymatic processing of
corn as high fructose corn syrup (HFCS), which is increasingly used in the food industry as a cheaper,
tasteless, readily available sweetener in many products, such as sodas, candies, and artificial fruit
juices [57]. Furthermore, this monosaccharide is also present as disaccharide, the sucrose, in complex
with glucose [58]. The main fructose carriers, GLUT-5 and GLUT-2, two members of the glucose
transport family (GLUT), provide for the passive uptake of fructose: GLUT-5, located on the brush
border membrane of human small intestine enterocytes, is a glucose-independent transporter with low,
saturable uptake capacity; GLUT-2 is a high-capacity, glucose-dependent fructose co-transporter. In
addition to fructose, GLUT-2 is also a transporter for glucose and galactose, constitutively located on
the basolateral membrane. In specific conditions, GLUT-2 can be expressed on the apical membrane.
Fructose malabsorption should not be confused with hereditary fructose intolerance (a metabolic
disease whose incidence is estimated to be 1 in 25,000 individuals) in which a lack of functional
aldolase B results in an accumulation of fructose-1-phosphate in the liver, kidneys, and intestine [57],
causing hypoglycemia, nausea, bloating, abdominal pain, diarrhea, and vomiting [57]. A useful test
for diagnosis of fructose malabsorption is the hydrogen breath test [58], by which the H2 produced is
measured noninvasively in collected samples of expired breath after the ingestion of a standardized
dose of 0.5 g/kg of fructose to a maximum of 25 g dissolved in water (sensitivity and specificity both
80% to 90%) [14]. The diagnosis is confirmed by an increase of ě20 ppm in H2 or ě10 ppm in CH4
levels over the baseline twice in succession and abdominal discomfort after the consumption of the test
dose. However, according to other authors, a negative breath test result does not exclude a positive
response to fructose restriction, so the hydrogen breath test does not seem to be the appropriate
diagnostic means to predict the response to the diet [59]. Fructose malabsorption can be secondary
to intestinal injury (induced by several diseases such as celiac disease) [60–63]. The rate of children
who tested positive for malabsorption on a fructose breath test is significantly higher in younger age
groups (<9 years) [64]. It was hypothesized that the rapid decrease of the fructose malabsorption
from infancy to higher age could reflect the normal developmental maturation of the mechanisms
of fructose absorption [64]. Moreover, the importance of fructose malabsorption is hypothesized to
depend on the ratio of fructose to glucose, but the specific mechanism responsible has yet to be clearly
elucidated [62]. In fact, the active reabsorption of glucose from the small intestine is due to the transport
system SGLT-1/sodium-glucose cotransporter. When the ingested glucose is transported by SGLT1,
GLUT2 is activated and inserted into the apical membrane, so the co-ingestion of glucose greatly
enhances fructose absorption [58,65–74]. A second mechanism has been postulated: fructose with
other solutes is absorbed by a paracellular transport system, based on the opening of tight junctions
induced by glucose absorption [58]. These mechanisms with glucose could explain the reason why,
when the concentration of fructose in a certain food is present in excess of glucose concentration, some
individuals may develop fructose malabsorption [72–74]. On the other hand, sorbitol seems to have a
negative effect on fructose absorption. This sugar alcohol (polyol) can be transformed into fructose,
blocking GLUT-5 and leading to aggravation of the fructose uptake disorder [75]. The treatment
of fructose malabsorption is based on a reduction of fructose intake lower than 10 g/day, and the
elimination of sugar alcohols and alcoholic beverages (Table 5). Moreover, it is essential to educate
patients about the importance of a balanced intake of fructose and glucose, for the reasons described
above. Furthermore, the intake of xylose isomerase as a dietary supplement, increasing the conversion
of fructose to glucose, seems to ameliorate the symptoms of fructose malabsorption [76]. Using these
dietetic strategies, it is possible to obtain remission of symptoms in 60% to 90% of cases [76].
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Table 5. Low fructose diet.
Foods to Avoid
All fruits
Broccoli, carrots, cauliflower, green beans, green peppers, sweet potatoes, tomatoes
Beans, peas
Corn
Fructose, honey, high-fructose corn syrup, sorbitol, jams, gelatin desserts, candies, all desserts sweetened with
fructose
Condiments such as barbeque sauce, ketchup, sweet and sour sauce, pancake syrup, plum sauce, chutney, etc.
Foods Allowed
Asparagus, celery, chives, cucumber, kale, lettuce, parsnips, pumpkin, radish, scallions, spinach, spinach,
white potatoes, shallots, zucchini
All cereals
All meat, fish, and eggs
All dairy
All fats
Sugar (sucrose), molasses, saccharine
4.2. Sorbitol Intolerance
Sorbitol is a carbohydrate naturally present in fruits and juices. It is also used in commercially
products such as drugs, sweets, dietetic foods, and chewing gum. Sorbitol absorption is dose and
concentration related. Sorbitol H2 breath test is effective in detecting small bowel damage with a
relevant reduction of absorption surface, but it is not specific for any condition responsible for intestinal
malabsorption [14]. A diet with low sorbitol concentration is indicated in Table 6.
Table 6. Low sorbitol diet.
Foods to Avoid
Apple, apricot, blackberry, cherry, date, fig, nectarine, pear, peach, plum, raisin, and other dried fruits
Sugar-free chewing gum and candies
Diabetic foods and drinks
Diet and light drinks
Foods that contain the initials E420 in the list of ingredients
Foods Allowed




All meat, fish, and eggs
Milk and dairy products
All fats
Sugar, honey, fructose, cocoa, jams, gelatin desserts, molasses, all desserts made with sugar, marmalade,
chocolate, commercial cookies and cakes with added sugar, sweetened drinks, artificial sweeteners: aspartame,
saccharine, mannitol, isomalt, xylitol (cough drops, gums, mints)
4.3. Trehalose Intolerance
Trehalose is a disaccharide composed of two glucose molecules and found in mushrooms
and algae [77]. Intestinal trehalose, a brush border enzyme, is a beta-galactosidase that catalyzes
the hydrolysis of trehalose to two glucose molecules for absorption. It is present throughout the
small intestine, with the highest levels in the proximal jejunum [77]. Isolated trehalose deficiency
represents an autosomal dominant condition, and occurs in at least 8% of Greenland’s population [58].
Nevertheless, only three cases have been reported elsewhere, two of whom were first-degree relatives.
Up to now, only a study by Arola is available about trehalose malabsorption and H2 breath testing [58].
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In this work, a 25 g oral trehalose load test was performed in 64 subjects. Trehalase activity was
determined in serum and on a duodenal biopsy specimen and symptoms of intolerance were recorded.
Intolerant subjects were best differentiated from tolerant subjects by changes in breath gases (hydrogen
and methane) and duodenal trehalase/sucrase ratio. The change in breath gases correlated inversely
with duodenal trehalase activity [58]. Nevertheless, no conclusive evidence is available to support
trehalose H2 breath testing in clinical practice and, therefore, the performance of this test is not
recommended [63].
4.4. FODMAPs Intolerance
Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) are a
group of short-chain carbohydrates poorly absorbed at the intestinal level. A list of high FODMAPs
foods is reported in Table 7.
Table 7. Main high FODMAPs foods.
















fennel, onions, garlic, leeks













These highly osmotic substances are fermented by gut bacteria and may induce gastrointestinal
symptoms by luminal distention or through direct action at the intestinal level by an as-yet undefined
mechanism [78]. The therapeutic approach to FODMAPs intolerance is based on an exclusion diet
(Table 8). Considering the high number of foods included in the FODMAPs list and that some people
may be more sensitive to some groups of FODMAPs than others, the exclusion diet should be carefully
tailored by an expert pediatric nutritionist based on the clinical history and the results of selected
sugars breath tests [79]. The FODMAPs free diet is usually recommended for 4–6 weeks. Following
this period of elimination, patients are encouraged to “challenge” themselves with different groups
of FODMAPs, in order to determine which group of FODMAPs they are sensitive to, and then to
liberalize the diet as much as possible.
Table 8. Low FODMAPs diet.
Foods to limit
Milk (from cow, sheep, or goat), butter, cottage cheese, ice cream, creamy/cheesy sauces,
sweetened condensed milk, soft cheeses (brie, ricotta), mozzarella, whipped cream, yogurt
Legumes (beans, chickpeas, peas, lentils)
Wheat, einkorn, emmer, kamut, spelt, rye
Artichokes, asparagus, beets, leeks, broccoli, Brussels sprouts, cabbage, cauliflower, fennel, green beans,
mushrooms, garlic, onions
Avocado, apples, apricots, dates, canned fruit, cherries, dried fruits, figs, mango, pears, papaya, peaches, plums,
prunes, persimmon, watermelon
Honey, jams, jellies, molasses, artificial sweeteners: sorbitol, mannitol, isomalt, xylitol (cough drops, gum, mints)
Foods allowed
Lactose-free milk and lactose-free dairy, hard cheeses (cheddar, Parmesan, pecorino, Swiss)
Wheat-free grains: rice, corn, quinoa, tapioca, buckwheat
Banana, berry, cantaloupe, grape, grapefruit, kiwi, lemon, lime, mandarin, orange, pineapple
Bell peppers, cucumbers, carrots, celery, eggplant, lettuce, leafy greens, olives, pumpkin, potatoes, tomatoes,
zucchini, most spices and herbs
Sugar
All fats
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The challenge phase can be done either by adding foods high in a particular group of FODMAPs
for a day, or by starting with a very small amount of FODMAPs from one group and gradually adding
more items into the diet in order to determine the individual tolerance. If there is little efficacy after six
weeks of elimination, the diet should be discontinued. However, some patients who report inadequate
symptom improvement with the diet still report that their symptoms are aggravated when they eat
high-FODMAPs foods [79].
5. Conclusions
Intolerance to carbohydrates is common in childhood. The pathophysiologic mechanisms are
variable, leading to different onset age and management. The therapeutic approach is based on dietary
treatment that should be supervised by an experienced nutritionist who can tailor the diet according
to the necessities of the patient limiting the risk of malnutrition. Genetics is providing new insights
through molecular analysis for early diagnosis of severe forms of intolerance to carbohydrates.
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